Phenacetin (B1453): Non-Opioid Analgesic for Pharmacokinetic Research

Executive Summary: Phenacetin (N-(4-ethoxyphenyl)acetamide) is a non-opioid analgesic and antipyretic agent historically used for pain and fever relief, lacking anti-inflammatory properties [Product]. It exhibits a molecular weight of 179.22 g/mol, is insoluble in water, but shows solubility ≥24.32 mg/mL in ethanol (ultrasound-assisted) and ≥8.96 mg/mL in DMSO, making it suitable for in vitro pharmacokinetic workflows [DOI]. Phenacetin is no longer approved for clinical use due to nephrotoxicity but is extensively used in scientific research as a substrate in drug absorption and metabolism studies [DOI]. Advanced hiPSC-derived intestinal organoids enable modeling of human-relevant drug transport and metabolism, with phenacetin serving as a test compound [DOI]. All research applications must account for its non-clinical, research-only status, as indicated by regulatory withdrawals [Product].

Biological Rationale

The human small intestine is the principal site for absorption and initial metabolism of orally administered drugs. Intestinal epithelial cells, especially enterocytes, express drug transporters and cytochrome P450 enzymes, including CYP3A4, which mediate first-pass metabolism [DOI]. Phenacetin is used as a probe compound to evaluate metabolic capacity and transporter activity in these models. Human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) recapitulate the cellular complexity of the intestine, supporting advanced pharmacokinetic studies [DOI]. These organoids provide a stable, reproducible, and human-relevant assay system for benchmarking compound absorption, efflux, and metabolism, overcoming limitations of traditional animal models and immortalized cell lines.

Mechanism of Action of Phenacetin

Phenacetin acts as a non-opioid analgesic and antipyretic agent. It inhibits prostaglandin synthesis in the central nervous system, reducing pain sensation and fever, but lacks significant anti-inflammatory effects [Product]. Its parent compound undergoes hepatic biotransformation, primarily by CYP1A2, to form paracetamol (acetaminophen), which is responsible for the majority of the analgesic and antipyretic effects [DOI]. In pharmacokinetic research, phenacetin is frequently used as a model substrate to measure CYP activity, evaluate enterocytic drug metabolism, and benchmark transport efficiency across in vitro intestinal barriers.

Evidence & Benchmarks

• Phenacetin is metabolized by CYP1A2 in human liver microsomes and by CYP3A enzymes in intestinal models (Saito et al., 2025, https://doi.org/10.1016/j.ejcb.2025.151489).
• hiPSC-derived intestinal organoids exhibit functional CYP activity and transporter expression, enabling accurate modeling of phenacetin pharmacokinetics (Saito et al., 2025, https://doi.org/10.1016/j.ejcb.2025.151489).
• Phenacetin exhibits solubility ≥24.32 mg/mL in ethanol (with ultrasound, 25°C) and ≥8.96 mg/mL in DMSO, but is insoluble in water (ApexBio, https://www.apexbt.com/phenacetin.html).
• Phenacetin was withdrawn from clinical markets due to nephrotoxicity and is not approved for diagnostic or therapeutic use (Health Canada, 1973; https://www.apexbt.com/phenacetin.html).
• hiPSC-IOs support long-term propagation and can be cryopreserved, facilitating reproducible pharmacokinetic assays using phenacetin as a model compound (Saito et al., 2025, https://doi.org/10.1016/j.ejcb.2025.151489).

Applications, Limits & Misconceptions

Phenacetin, supplied at ≥98% purity with Certificate of Analysis (COA), HPLC, NMR, and MSDS documentation, is intended for use in scientific research only [Product]. Its primary applications include:

• Benchmarking metabolic activity of CYP1A2 and CYP3A enzymes in hiPSC-IOs and human microsomes.
• Assessing drug absorption, efflux, and transport in intestinal organoid and cell culture models.
• Serving as a reference compound in analytical method development and validation.

This article expands on prior work such as 'Phenacetin in Pharmacokinetic Research: Solubility, Model...', by providing new benchmarks for hiPSC-derived intestinal organoid models and clarifying regulatory limitations for research use only. For a broader systems-level perspective on solubility and transport dynamics, see 'Phenacetin in Next-Gen Intestinal Organoid PK: Beyond Sol...'; here, we emphasize experimental validation and regulatory context.

Common Pitfalls or Misconceptions

• Phenacetin is not suitable for clinical or diagnostic applications due to its nephrotoxic risks and regulatory withdrawal [Product].
• It does not possess anti-inflammatory properties; use is limited to analgesia and antipyresis in historical contexts [Product].
• Long-term storage of phenacetin solutions is not recommended; fresh preparation is required for reproducible assay conditions [Product].
• Phenacetin's insolubility in water limits its use in aqueous-based in vitro systems without suitable co-solvents or formulation strategies [Product].
• Results from animal models or non-human cell lines may not extrapolate to human-relevant outcomes due to species-specific differences in metabolism [DOI].

Workflow Integration & Parameters

Phenacetin (SKU: B1453) is provided as a high-purity powder and should be stored at -20°C to maintain stability ([Product]). For in vitro experiments, dissolve phenacetin in ethanol (≥24.32 mg/mL, 25°C, ultrasound) or DMSO (≥8.96 mg/mL) prior to dilution into assay media. Avoid aqueous media without solubilizers, as phenacetin is insoluble in water. Prepare fresh solutions prior to use; avoid long-term storage of working stocks. Typical research workflows include application of phenacetin to hiPSC-derived organoid monolayers or 3D cultures, followed by measurement of parent compound and metabolites using HPLC or LC-MS/MS. For detailed solubility and model selection guidance, see 'Phenacetin in Advanced Intestinal Organoid Pharmacokinetics', which this article extends by providing updated source-linked parameters and regulatory clarifications.

Conclusion & Outlook

Phenacetin (N-(4-ethoxyphenyl)acetamide) is a well-characterized, non-opioid analgesic compound used as a reference substrate in pharmacokinetic research. Its defined solubility and metabolic pathways make it a preferred choice for benchmarking CYP activity and drug transport in hiPSC-derived intestinal organoids. Due to regulatory withdrawal, its use is restricted to non-clinical, research-only applications. Continued refinement of human-relevant in vitro models will increase the utility of phenacetin and related compounds in predictive drug absorption and metabolism studies. For product specifications, quality control, and ordering, refer to the Phenacetin B1453 product page.